Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Add as a preferred source on Google
SAN DIEGO, Feb. 21, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2016 financial and operating results after the close of U.S. financial markets on Tuesday, February 28, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | February 28, 2017 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 73756754 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
